AI-Powered Confidential Intermediary

Unlocking the full value of scientific discovery

SynergyVault is the confidential AI that sits between companies, reads what each one has and needs, and finds connections none of them could see — including combinations that create entirely new innovations.

$250B+
Annual R&D across 2,330+ companies
88%
Of drugs never reach market
~0%
Systematic capture rate
10+
Industries with hidden synergies
Three capabilities. One platform.
No human — including SynergyVault — ever sees the underlying data. The AI is the only reader. Companies see only anonymized notifications until both sides consent.
🔍

It finds what you need.

Describe your challenge. The AI searches the entire corpus of participating companies and finds who can help — across industries you'd never think to look.

💰

It finds who needs what you have.

Deposit a capability — even a discontinued program generating zero revenue. The AI finds buyers you didn't know existed and creates a licensing revenue stream.

✦

It invents what nobody imagined.

Our Synthesis engine proposes novel multi-company combinations that no participant conceived independently. The AI doesn't just match — it creates.

Five stages. Full confidentiality.
01

Secure Onboarding

Master Participation Agreement. Encrypted channel established.

→
02

Discovery Ingestion

Manual deposits or Scout agent auto-discovers assets inside your systems.

→
03

AI-Only Matching

Full-fidelity processing. No human reads the data. Ever.

→
04

Anonymized Notification

Confidence score and estimated value only. No identities revealed.

→
05

Facilitated Introduction

Only after mutual consent. Moderated disclosure and deal tracking.

🔒
The AI reads everything. No human reads anything. This is not a policy — it is a technical architecture. Homomorphic encryption and secure enclaves ensure that no human, including SynergyVault engineers, ever accesses raw submissions.
Your AI never stops looking.
Scout deploys inside your company's own systems — ELNs, project databases, archives, patent drafts — and continuously discovers assets that could generate value on the platform.

Deploys inside your walls

Scans your internal systems. Nothing leaves without explicit human approval. Every listing goes through a review queue.

5 minutes to review

Scout pre-drafts listings from what it finds. You approve, edit, or reject with one click — versus weeks to assign a cataloging project.

Start with zero risk

Not ready for active programs? Begin with discontinued IP through our Vault Preview — zero cost, zero risk, simplified agreement. If a match is found, you earn revenue from a $0 asset.

2,330+ companies. 10+ industries.
Life Sciences — The Beachhead
870
Pharma, biotech, and medical device companies. $250B+ annual R&D. MELLODDY proved 10 competing pharma companies will collaborate on confidential data infrastructure.
Cross-Industry Expansion
1,460
Aerospace, automotive/EV, energy, advanced materials, semiconductors, agtech, and telecom. The highest-value matches cross disciplinary boundaries.
Y7 Projected Revenue
$1.47B
96% EBITDA margins. 100 employees. Only 16% market penetration by Year 7. The runway is enormous.
Revenue Model
4 streams
Annual platform fees, Q&A query credits, introduction fees at mutual opt-in, and 1-3% success fees on deal value. Network effects grow combinatorially.
Built to earn trust.
Scientific credibility in how discoveries are generated + proven platform-building at scale. The combination that earns a seat in the C-suite.
Robert Gordon, MD
Co-Founder
Clinical Associate Professor (Affiliated), Cardiothoracic Surgery, Stanford. Board-certified, 50+ years in medicine. Firsthand understanding of how R&D discoveries are generated, discontinued, and what value remains.
Rob Frohwein
Co-Founder
Co-founder & CEO, Kabbage — acquired by American Express for ~$850M. Originated $16B+ in loans to 500K+ businesses. 25+ issued patents in fintech and data analytics. Same infrastructure-play instinct driving SynergyVault from IP database to confidential intermediary infrastructure.
See the matching engine in action.
Experience all three modalities with real pharmaceutical data: cross-industry asset matching, anonymous Q&A exchange, and AI-generated synthesis proposals. No signup required.

78% match confidence

Materials company's discontinued chemistry → Oncology pharma's ADC program. Cross-industry bridge with concrete value.

3-tier anonymity

Watch two companies exchange information about cell therapy manufacturing through progressive identity reveals.

Novel combinations

AI-proposed 3+ company collaborations that no single participant would have imagined independently.

The upper-right quadrant is unoccupied.

Confidential + Active + Passive + Generative. No one else is doing this.

See the Platform Live → Request a Conversation